Tumor necrosis factor inhibitors and methotrexate are associated with decreased COVID-19-related hospitalization: Follow up of "Clinical outcomes of COVID-19 in patients taking tumor necrosis factor inhibitors and methotrexate".

Cahn, Rachel Tallman; Zinn, Zachary; Kolodney, Michael S

Cahn, Rachel Tallman; Zinn, Zachary; Kolodney, Michael S.

Cahn RT; Department of Dermatology, West Virginia University, Morgantown, West Virginia. Electronic address: rmtallman@hsc.wvu.edu.
Zinn Z; Department of Dermatology, West Virginia University, Morgantown, West Virginia.
Kolodney MS; Department of Dermatology, West Virginia University, Morgantown, West Virginia. Electronic address: michael.kolodney@hsc.wvu.edu.

J Am Acad Dermatol ; 88(6): 1385-1386, 2023 06.

Article in English | MEDLINE | ID: covidwho-2236089

Subject(s)

COVID-19; Methotrexate; Humans; Methotrexate/therapeutic use; Tumor Necrosis Factor Inhibitors/adverse effects; Follow-Up Studies; Hospitalization; Tumor Necrosis Factor-alpha

Keywords

COVID-19; SARS-CoV-2; TNF-alpha; coronavirus; methotrexate; tumor necrosis factor-alpha inhibitor

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Methotrexate / COVID-19 Type of study: Cohort study / Prognostic study Limits: Humans Language: English Journal: J Am Acad Dermatol Year: 2023 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google